debate: should jak2 inhibitors be used for lower-risk mf, or only on-label (higher-risk)? - yes
Published 9 years ago • 280 plays • Length 15:48Download video MP4
Download video MP3
Similar videos
-
17:09
debate: should jak2 inhibitors be used for lower-risk mf, or only on-label (higher-risk)? - not yet
-
24:12
debate: survival benefit of jak2 inhibitors in myelofibrosis
-
15:55
debate: should jak inhibitors use be limited to hydroxyurea-resistant/intolerant pv patients? - yes
-
20:53
debate: position of jak2 inhibitors as second line therapy in polycythemia vera
-
24:52
combination therapy with jak2 inhibitors in mpn
-
25:13
update on jak inhibitors for myelofibrosis: there is more than one
-
29:27
my view on current and future use of jak inhibitors for et, pv, and mf
-
17:26
debate: to maintain or not to maintain? immunomodulators vs. pi - yes (proteasome inhibitors)
-
37:14
risk-adapted treatment in myelofibrosis: jak inhibitors and novel combination therapies
-
20:42
beyond jak2 inhibitors: new targets and new agents
-
25:59
beyond jak2 inhibitors: new targets and new agents
-
21:52
stem cell transplant for myelofibrosis in the jak2 inhibitor era
-
18:50
jak inhibitors for et and pv: what have we learned so far?
-
16:10
stem cell transplant for myelofibrosis in the jak2 inhibitor era
-
2:06
second-line myelofibrosis treatment – the potential of jak2 inhibitor ns-018
-
3:22
jak2 inhibition in the treatment of myelofibrosis
-
31:14
update on jak2 inhibitors by srdan verstovsek, md
-
1:43
dr. tal zaks on the jak2 inhibitor sar302503 in myelofibrosis
-
31:14
update on jak2 inhibitors by srdan verstovsek, md